Geode Capital Management LLC Increases Position in Femasys Inc. (NASDAQ:FEMY)

Geode Capital Management LLC raised its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 4.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 216,164 shares of the company’s stock after purchasing an additional 9,681 shares during the period. Geode Capital Management LLC’s holdings in Femasys were worth $238,000 as of its most recent SEC filing.

Separately, Virtu Financial LLC bought a new position in Femasys during the 4th quarter valued at approximately $25,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Femasys in a research note on Friday, March 28th.

Femasys Stock Performance

Shares of FEMY stock opened at $1.16 on Friday. The company has a market capitalization of $31.49 million, a price-to-earnings ratio of -1.43 and a beta of -2.55. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys Inc. has a one year low of $0.86 and a one year high of $1.80. The company’s 50-day moving average is $1.34 and its 200 day moving average is $1.24.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.66 million. Sell-side analysts expect that Femasys Inc. will post -0.86 EPS for the current fiscal year.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.